Recently, the focus on inhalation drug delivery technology application development of innovative pharmaceutical enterprises "credit split" announced that has completed nearly 200 million yuan of total amount of B round, led by the national science investment, yuan birth mother funds, venture capital, co-win, sea before day peak, leaning back, capital and famous investment institutions, such as, bank capital as a financial consultant.
"Risepril" said that this round of financing will mainly be used to expand the company's existing GMP production line, carry out high-end inhalation preparations and inhalation of innovative drugs pipeline layout.
"Pipes Capital Pte.Ltd. focuses on pharmaceutical innovation companies," said Richard Bocker, chief investment officer of Pipes Capital Pte.Ltd., who served as financial adviser for the round. Among them, high-end preparations, especially inhalation preparations, have always been the technical difficulties that domestic pharmaceutical enterprises are committed to overcome, and dry powder inhalants belong to the category of the highest technical barriers among inhalants. Centring on the powder aerosol technology platform, Risepril continues to develop drugs covering asthma, COPD and other indications to gradually meet the urgent clinical needs. We are optimistic about "Raisepoll" under the leadership of general manager Chen, become the future domestic powder aerosol leader.
The following is reprinted from: Artery Network
Text: Wang Shiwei
Artery Network is the first to learn that Risepril, an innovative pharmaceutical company focused on the application and development of inhaled drug delivery technology, has recently announced that it has completed a round B financing with a total amount of nearly 200 million yuan. This round of financing was led by Guoke Investment, followed by Yuansheng Venture Capital, Tongchuang Weiye, Qianhai Mother Fund, Tianfeng Capital, Yifeng Capital and other well-known investment institutions. Datong Capital acted as the financial adviser. It is understood that this round of financing will mainly be used to expand the company's existing GMP production line and develop the pipeline layout of high-end inhalation preparations and inhalation innovative drugs.
Prior to this, "Risepool" has obtained tens of millions of yuan of A round financing from Huige Capital, Yanghe Investment, Gree Gold Investment, Condeli, and Zhuhai Science Venture Capital in 2019.
"Rick split" was founded in 2018, is committed to the world's leading respiratory inhalation drug formula technology and equipment research and development, production, product line covers the respiratory system all series of products in development, involving Asthma (Asthma) and chronic obstructive pulmonary disease (COPD), the diseases of the central nervous system (CNS), and other clinical treatment field of demand, plans for future 2 years will be 2 ~ 3 drugs in development to clinical trials.
Chen Yongqi, chairman of Rispli, expressed his gratitude to the new and old investors for their trust and support to Rispli's technology and team, as well as their profound grasp of the development trend of high-end inhalation preparations in this niche field. The domestic inhalation industry is relatively backward, with over 90% of the market share occupied by overseas companies for a long time. "Risepril" will deeply explore the field of high-end inhalation preparations, live up to the expectations of the public, lead the innovation, bring international standard good medicine with favorable price for domestic patients, and become a preparation platform company with international influence.
Mr. Yin Lei, Managing Director of Guoxi Investment, pointed out that Dr. Chen Yongqi has very rich experience in the field of inhalation preparations. He has led and completed the research and development of many original inhalation preparations and highly difficult imitation inhalation drugs. After setting up his own business, he established the top team in the field of powder and mist inhalation preparations in China. Risepril's inhalation development technology platform not only enables the development of generics of refractory inhalation formulations, but also enables the development of new drugs with improved dosage forms to meet a wide range of clinical needs. Guoke Investment is very pleased to participate in this round of financing with many professional medical investment institutions, and will also provide continuous support for the better development of the company in the future.
The B-round investors, such as Tianfeng Capital, Yuansheng Venture Capital, Tongchuang Wai, Qianhai Mother Fund and Yifeng Capital, value the ability of "Risepril" to build high competitive barriers in inhaled preparations and pharmaceuticals. The company is a rare technological platform enterprise with original creativity in China. The Series B investors said that they will help the company to achieve the leap from Biotech to Pharma and become the global leader in dry powder inhalation preparations, committed to innovation and the benefit of patients.
Prior to founding Riespll, Dr. Chen worked at Vectura, a world leader in the development of inhalation drug delivery technology, and served as chief scientist of inhalation products. He has more than 20 years of experience in the development of inhalation products. Dr. Chen has led and participated in the successful development of 13 major aerosol and powder aerosol products among the 17 inhaled drugs on the global market.
Among the generics, the only generics in the world listed in the United States and the European Union are Seretide, the European Union listed BiBique, the original new drugs, Novartis' Geron and Cirenon, and GSK's Ellipta series of new drugs, all developed by Dr. Chen in Vectura. Since its establishment in 2018, "Rispli" has rapidly established a technical and management team composed of domestic and overseas experts in physics, pharmacology, clinical medicine and other experienced talents, and rapidly promoted the implementation of dry powder preparation platform technology.
Dr. Chen Yongqi told Artery Network that Risepril has built four major platforms for inhalation therapy by starting from the platform of dry powder, which has the highest technical barrier and is also the team's best expertise. In the future, Risepoll will adopt the dual-wheel driven research and development mode of "high-end generic drugs + innovative drugs" to break the near-monopoly position of foreign companies in the existing inhaled powder and aerosol products, and develop more high-quality innovative inhaled drugs to benefit patients at home and abroad.
